Logo image of CNSP

CNS PHARMACEUTICALS INC (CNSP) Stock Fundamental Analysis

USA - NASDAQ:CNSP - US18978H5081 - Common Stock

7.51 USD
-0.09 (-1.18%)
Last: 10/30/2025, 8:00:29 PM
7.21 USD
-0.3 (-3.99%)
After Hours: 10/30/2025, 8:00:29 PM
Fundamental Rating

2

Overall CNSP gets a fundamental rating of 2 out of 10. We evaluated CNSP against 192 industry peers in the Pharmaceuticals industry. CNSP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CNSP has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CNSP had negative earnings in the past year.
CNSP had a negative operating cash flow in the past year.
In the past 5 years CNSP always reported negative net income.
In the past 5 years CNSP always reported negative operating cash flow.
CNSP Yearly Net Income VS EBIT VS OCF VS FCFCNSP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

CNSP has a worse Return On Assets (-106.55%) than 78.13% of its industry peers.
The Return On Equity of CNSP (-117.78%) is worse than 64.06% of its industry peers.
Industry RankSector Rank
ROA -106.55%
ROE -117.78%
ROIC N/A
ROA(3y)-465.36%
ROA(5y)-324.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CNSP Yearly ROA, ROE, ROICCNSP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K

1.3 Margins

CNSP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CNSP Yearly Profit, Operating, Gross MarginsCNSP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

CNSP has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CNSP has been increased compared to 5 years ago.
CNSP has a better debt/assets ratio than last year.
CNSP Yearly Shares OutstandingCNSP Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20K 40K 60K 80K 100K
CNSP Yearly Total Debt VS Total AssetsCNSP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -9.40, we must say that CNSP is in the distress zone and has some risk of bankruptcy.
CNSP has a worse Altman-Z score (-9.40) than 67.19% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that CNSP is not too dependend on debt financing.
CNSP has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: CNSP outperforms 56.77% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -9.4
ROIC/WACCN/A
WACCN/A
CNSP Yearly LT Debt VS Equity VS FCFCNSP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

A Current Ratio of 10.22 indicates that CNSP has no problem at all paying its short term obligations.
CNSP's Current ratio of 10.22 is amongst the best of the industry. CNSP outperforms 82.29% of its industry peers.
A Quick Ratio of 10.22 indicates that CNSP has no problem at all paying its short term obligations.
The Quick ratio of CNSP (10.22) is better than 82.29% of its industry peers.
Industry RankSector Rank
Current Ratio 10.22
Quick Ratio 10.22
CNSP Yearly Current Assets VS Current LiabilitesCNSP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 99.65% over the past year.
EPS 1Y (TTM)99.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.84%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CNSP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.13% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y92.81%
EPS Next 2Y40.65%
EPS Next 3Y25.58%
EPS Next 5Y18.13%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CNSP Yearly Revenue VS EstimatesCNSP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 50M 100M 150M 200M
CNSP Yearly EPS VS EstimatesCNSP Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -100K -200K -300K -400K -500K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CNSP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CNSP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CNSP Price Earnings VS Forward Price EarningsCNSP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CNSP Per share dataCNSP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -50 -100 -150 -200 -250

4.3 Compensation for Growth

CNSP's earnings are expected to grow with 25.58% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.65%
EPS Next 3Y25.58%

More info and screens

0

5. Dividend

5.1 Amount

CNSP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CNS PHARMACEUTICALS INC

NASDAQ:CNSP (10/30/2025, 8:00:29 PM)

After market: 7.21 -0.3 (-3.99%)

7.51

-0.09 (-1.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-13 2025-11-13
Inst Owners7.44%
Inst Owner Change0%
Ins Owners0%
Ins Owner Change0%
Market Cap4.28M
Revenue(TTM)N/A
Net Income(TTM)-15458600
Analysts82.5
Price Target53.04 (606.26%)
Short Float %8.02%
Short Ratio0.82
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)642.86%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1026.19%
EPS NY rev (1m)0%
EPS NY rev (3m)-49.37%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.33
P/tB 0.33
EV/EBITDA N/A
EPS(TTM)-276.72
EYN/A
EPS(NY)-10.38
Fwd EYN/A
FCF(TTM)-36.6
FCFYN/A
OCF(TTM)-36.59
OCFYN/A
SpS0
BVpS23.03
TBVpS23.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -106.55%
ROE -117.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-465.36%
ROA(5y)-324.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.22
Quick Ratio 10.22
Altman-Z -9.4
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)74.13%
Cap/Depr(5y)104.48%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.84%
EPS Next Y92.81%
EPS Next 2Y40.65%
EPS Next 3Y25.58%
EPS Next 5Y18.13%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y2.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-68.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-68.89%
OCF growth 3YN/A
OCF growth 5YN/A

CNS PHARMACEUTICALS INC / CNSP FAQ

What is the fundamental rating for CNSP stock?

ChartMill assigns a fundamental rating of 2 / 10 to CNSP.


What is the valuation status of CNS PHARMACEUTICALS INC (CNSP) stock?

ChartMill assigns a valuation rating of 1 / 10 to CNS PHARMACEUTICALS INC (CNSP). This can be considered as Overvalued.


Can you provide the profitability details for CNS PHARMACEUTICALS INC?

CNS PHARMACEUTICALS INC (CNSP) has a profitability rating of 0 / 10.


What is the earnings growth outlook for CNS PHARMACEUTICALS INC?

The Earnings per Share (EPS) of CNS PHARMACEUTICALS INC (CNSP) is expected to grow by 92.81% in the next year.